174 patents
Page 8 of 9
Utility
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
6 Jul 20
Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH).
Leonard Bell, Russell P. Rother, Mark J. Evans
Filed: 27 Feb 20
Utility
ANTI-C5A Antibodies
1 Jul 20
The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
Russell P. ROTHER, Douglas L. SHERIDAN, Paul P. TAMBURINI, Yuchun ZHANG
Filed: 11 Sep 19
Utility
Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients by an Inhibitor of Complement
24 Jun 20
Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH).
Leonard BELL, Russell P. ROTHER, Mark J. EVANS
Filed: 27 Feb 20
Utility
Methods of Treating a Subject with an Alkaline Phosphatase Deficiency
10 Jun 20
Disclosed herein are methods for treating a subject with an alkaline phosphatase deficiency, further comprising monitoring additional analytes, e.g., calcium, parathyroid hormone and/or vitamin D, with treatment modifications as indicated by the levels, e.g., serum levels, of the additional analytes.
Tatjana ODRLJIN
Filed: 18 Feb 20
Utility
Dosage and Administration of ANTI-C5 Antibodies for Treatment of Protein-losing Enteropathy In Patients
3 Jun 20
Provided are methods for clinical treatment of a protein-losing enteropathy, such as lymphangiectasia, using an anti-C5 antibody, or antigen binding fragment thereof, in patients (e.g., pediatric patients).
Orly Eshach ADIV, Camille BEDROSIAN, Hagit Baris FELDMAN, Alina KUROLAP, Susan Faas MCKNIGHT
Filed: 20 May 18
Utility
Methods of Replicating a Large Scale Eculizumab Production Cell Culture
3 Jun 20
Provided herein are methods of replicating a large scale eculizumab production cell culture in a small scale culture.
Hunter F. MALANSON, Pratik JALURIA
Filed: 9 Dec 19
Utility
ANTI-C5 Antibodies Having Improved Pharmacokinetics
20 May 20
The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders.
Bruce A. ANDRIEN, Jr., Douglas L. SHERIDAN, Paul P. TAMBURINI, Yi WANG
Filed: 22 Jan 20
Utility
Methods for Treating Complement-associated Disorders
6 May 20
The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders.
Russell P. ROTHER, Camille BEDROSIAN, Stephen P. SQUINTO, Leonard BELL
Filed: 10 Oct 19
Utility
N-acetyl-alpha-D-glucosaminidase deficiency compositions and methods
27 Apr 20
Compositions and methods relating to potentially pathogenic mutations in the nucleotide sequence of a human NAGLU gene.
Rui-Ru Ji, Andrew Hutchinson, Nina Jain, Christen D. Forbes
Filed: 10 Oct 17
Utility
Methods for Identifying the Health State of Hypophosphatasia (HPP) Patients
22 Apr 20
The disclosure features methods for identifying the health state of patients having hypophosphatasia (HPP).
Ioannis C. TOMAZOS, Andrew LLOYD
Filed: 9 Apr 18
Utility
Efficacy of an ANTI-C5 Antibody In the Prevention of Antibody Mediated Rejection In Sensitized Recipients of a Kidney Transplant
22 Apr 20
This disclosure provides methods for reducing antibody mediated rejection (AMR) in a human kidney transplant recipient, comprising administering a therapeutically effective amount of an anti-C5 antibody, or antigen-binding fragment thereof, to the recipient in a phased dosing schedule following reperfusion of a kidney allograft, wherein the recipient is sensitized to a human living donor and wherein the recipient receives about two or more weeks of desensitization therapy prior to transplantation.
Camille BEDROSIAN
Filed: 16 Apr 18
Utility
Methods for Treating Hypophosphatasia (HPP) In Adults and Adolescents
1 Apr 20
The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., an adult having HPP, such as an adult having pediatric-onset HPP, or an adolescent having HPP) exhibiting decreased pyrophosphate (PPi) or pyridoxal 5′-phosphate (PLP) concentrations in, e.g., a plasma sample, physical impairments, or decreased walking ability by administering a soluble alkaline phosphatase (sALP) to the patient.
Scott Edward MOSELEY, Andrew E. DENKER, Wei-Jian PAN
Filed: 28 Mar 18
Utility
Compositions Comprising an ANTI-C5 Antibody
1 Apr 20
The present application relates to methods and compositions employing an antibody that inhibits activation of the complement system and can be used to prevent or treat a pulmonary disease or condition.
Yi WANG
Filed: 8 Oct 19
Utility
Methods of treating a subject with an alkaline phosphatase deficiency
30 Mar 20
Disclosed herein are methods for treating a subject with an alkaline phosphatase deficiency, further comprising monitoring additional anaiytes, e.g., calcium, parathyroid hormone and/or vitamin D, with treatment modifications as indicated by the levels, e.g., serum levels, of the additional anaiytes.
Tatjana Odrljin
Filed: 27 Jan 16
Utility
Treating Seizure with Recombinant Alkaline Phosphatase
25 Mar 20
The present disclosure provides a method of treating seizure in a subject having aberrant alkaline phosphatase activities, comprising administering a therapeutically effective amount of at least one recombinant alkaline phosphatase to the subject.
Andre MAROZSAN, Denise DEVORE, Susan LIU-CHEN
Filed: 17 Oct 19
Utility
Compositions and Methods for the Treatment of Neuromyelitis Optica
25 Mar 20
Provided are methods of treating neuromyelitis optica spectrum disorder (NMOSD) in a subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (C5).
Fanny O'Brien
Filed: 19 Sep 19
Utility
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
16 Mar 20
Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH).
Leonard Bell, Russell P. Rother, Mark J. Evans
Filed: 4 Jul 17
Utility
Methods of treating atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria with anti-C5 antibodies
9 Mar 20
The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders.
Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini, Yi Wang
Filed: 13 Jan 19
Utility
Methods and Compositions for Treating Complement-associated Disorders
4 Mar 20
The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders.
Russell P. Rother
Filed: 19 Mar 19
Utility
Compositions and methods relating to genomic modifications in avian primordial germ cells
2 Mar 20
Methods of producing an exogenous protein in a bird egg are provided according to aspects of the present invention which include: providing transfected avian primordial germ cells by forming a complex of Cas protein and a guide nucleotide sequence in the avian primordial germ cells, whereby a donor DNA sequence is inserted into genomic DNA of the avian primordial germ cells under transcriptional control of a regulatory element that directs tissue-specific expression of the exogenous protein; introducing the transfected avian primordial germ cells into a population of recipient bird embryos and incubating the recipient bird embryos, generating germline chimera birds; obtaining a heterozygote and/or homozygote transgenic bird by breeding the germline chimera bird; and isolating the exogenous protein from an egg laid by a female transgenic bird.
Hao-Ming Chang, Markley C. Leavitt
Filed: 8 Aug 17